Sommadossi Jean-Pierre 4
4 · Atea Pharmaceuticals, Inc. · Filed Sep 19, 2024
Insider Transaction Report
Form 4
Sommadossi Jean-Pierre
DirectorPresident, CEO, and Chairman
Transactions
- Sale
Common Stock
2024-09-17$4.05/sh−33,941$137,318→ 5,890,053 total(indirect: By LLC) - Sale
Common Stock
2024-09-18$4.03/sh−22,187$89,469→ 5,867,866 total(indirect: By LLC) - Sale
Common Stock
2024-09-19$4.00/sh−1,841$7,367→ 5,866,025 total(indirect: By LLC)
Holdings
- 116,557
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.